Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 Capsules in Recurrent NMOSD-Related Optic Neuritis
ChiCTR2000031254Phase 2Recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dimethylaminomicheliolide in Neuromyelitis Optica Spectrum Disorder (NMOSD) and optic neuritis (ON) (4 arms), sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoints: Adverse events (AEs), Dose-limiting toxicities (DLTs) and 2 more. Started May 2020; status: recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)optic neuritis (ON)
Beyond the preview
Go deeper on ChiCTR2000031254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031254.